319 related articles for article (PubMed ID: 25271212)
1. Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy.
Li CF; He HL; Wang JY; Huang HY; Wu TF; Hsing CH; Lee SW; Lee HH; Fang JL; Huang WT; Chen SH
J Clin Pathol; 2014 Dec; 67(12):1056-61. PubMed ID: 25271212
[TBL] [Abstract][Full Text] [Related]
2. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
Yoon G; Lee H; Kim JH; Hur K; Seo AN
Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
[TBL] [Abstract][Full Text] [Related]
4. PLA2G2A overexpression is associated with poor therapeutic response and inferior outcome in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy.
He HL; Lee YE; Shiue YL; Lee SW; Lin LC; Chen TJ; Wu TF; Li CF
Histopathology; 2015 Jun; 66(7):991-1002. PubMed ID: 25393083
[TBL] [Abstract][Full Text] [Related]
5. High chloride channel accessory 1 expression predicts poor prognoses in patients with rectal cancer receiving chemoradiotherapy.
Chen TJ; He HL; Shiue YL; Yang CC; Lin LC; Tian YF; Chen SH
Int J Med Sci; 2018; 15(11):1171-1178. PubMed ID: 30123054
[No Abstract] [Full Text] [Related]
6. Overexpression of CPS1 is an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy.
Lee YY; Li CF; Lin CY; Lee SW; Sheu MJ; Lin LC; Chen TJ; Wu TF; Hsing CH
Tumour Biol; 2014 Nov; 35(11):11097-105. PubMed ID: 25099619
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy after neoadjuvant chemoradiation and curative resection for rectal cancer: is it necessary for all patients?
Jung KU; Kim HC; Park JO; Park YS; Park HC; Choi DH; Cho YB; Yun SH; Lee WY; Chun HK
J Surg Oncol; 2015 Mar; 111(4):439-44. PubMed ID: 25488390
[TBL] [Abstract][Full Text] [Related]
8. High EREG Expression Is Predictive of Better Outcomes in Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy.
Lin CY; Hsieh PL; Chou CL; Yang CC; Lee SW; Tian YF; Shiue YL; Li WS
Oncology; 2020; 98(8):549-557. PubMed ID: 32408308
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of REG4 confers an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy.
He HL; Lee YE; Shiue YL; Lee SW; Lin LC; Chen TJ; Wu TF; Hsing CH; Huang HY; Wang JY; Li CF
J Surg Oncol; 2014 Dec; 110(8):1002-10. PubMed ID: 25155043
[TBL] [Abstract][Full Text] [Related]
10. Deficiency in asparagine synthetase expression in rectal cancers receiving concurrent chemoradiotherapy: negative prognostic impact and therapeutic relevance.
Lin CY; Sheu MJ; Li CF; Lee SW; Lin LC; Wang YF; Chen SH
Tumour Biol; 2014 Jul; 35(7):6823-30. PubMed ID: 24729124
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of ANXA1 confers independent negative prognostic impact in rectal cancers receiving concurrent chemoradiotherapy.
Sheu MJ; Li CF; Lin CY; Lee SW; Lin LC; Chen TJ; Ma LJ
Tumour Biol; 2014 Aug; 35(8):7755-63. PubMed ID: 24810927
[TBL] [Abstract][Full Text] [Related]
12. Histological grading based on poorly differentiated clusters is predictive of tumour response and clinical outcome in rectal carcinoma treated with neoadjuvant chemoradiotherapy.
Reggiani Bonetti L; Lionti S; Domati F; Pagliani G; Mattioli E; Barresi V
Histopathology; 2017 Sep; 71(3):393-405. PubMed ID: 28425130
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
[TBL] [Abstract][Full Text] [Related]
14. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
Jao SW; Chen SF; Lin YS; Chang YC; Lee TY; Wu CC; Jin JS; Nieh S
Ann Surg Oncol; 2012 Oct; 19(11):3432-40. PubMed ID: 22739652
[TBL] [Abstract][Full Text] [Related]
15. The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
Edden Y; Wexner SD; Berho M
Colorectal Dis; 2012 May; 14(5):555-61. PubMed ID: 21689364
[TBL] [Abstract][Full Text] [Related]
16. The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy.
Lee YE; He HL; Shiue YL; Lee SW; Lin LC; Wu TF; Chang IW; Lee HH; Li CF
Tumour Biol; 2015 Sep; 36(10):7675-83. PubMed ID: 25929810
[TBL] [Abstract][Full Text] [Related]
17. Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer.
Mace AG; Gantt GA; Skacel M; Pai R; Hammel JP; Kalady MF
Dis Colon Rectum; 2013 Nov; 56(11):1217-27. PubMed ID: 24104995
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of DSG3 in rectal adenocarcinoma treated with preoperative chemoradiotherapy.
Chao TB; Li CF; Lin CY; Tian YF; Chang IW; Sheu MJ; Lee YE; Chan TC; He HL
Future Oncol; 2016 Jun; 12(12):1457-67. PubMed ID: 27040321
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer.
Abdul-Jalil KI; Sheehan KM; Kehoe J; Cummins R; O'Grady A; McNamara DA; Deasy J; Breathnach O; Grogan L; O'Neill BD; Faul C; Parker I; Kay EW; Hennessy BT; Gillen P
Colorectal Dis; 2014 Jan; 16(1):O16-25. PubMed ID: 24119076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
